Aberdeen Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Aberdeen Group’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,658,527	Closed	-$1.42M	–	975
2024 Q4	$1.42M	Hold	2,658,527	–	–	﹤0.01%	792
2024 Q3	$4.68M	Buy	2,658,527 +1,578,329	+146%	+$2.2M	0.01%	659
2024 Q2	$1.26M	Buy	1,080,198 +527,626	+95%	+$1.32M	﹤0.01%	798
2024 Q1	$5M	Hold	552,572	–	–	0.01%	667
2023 Q4	$6.01M	Buy	+552,572	New	+$4.14M	0.01%	641

Aberdeen Group's MRNS Position: Q1 2025 in Review

Aberdeen Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 2,658,527 shares — an estimated $1.42M sold.

Aberdeen Group first reported a position in MRNS in Q4 2023 and held it in 5 quarters. The position peaked at $6.01M in Q4 2023. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

Aberdeen Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
Aberdeen Group sold 2,658,527 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $1.42M.
Aberdeen Group first reported a position in Marinus Pharmaceuticals, Inc in Q4 2023 and held it in 5 quarters.
Aberdeen Group's Marinus Pharmaceuticals, Inc position peaked at $6.01M in Q4 2023.
0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on Aberdeen Group's 13F filing for Q1 2025, filed 13 May 2025.